CORONA Remedies shareholders and shareholding pattern
NSE: CORONABSE: 544644Pharmaceuticals & BiotechnologySmall Cap
Last close ₹2,051.10up ₹7.30 (0.36%)BSE ₹2,054.70
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,043.80.
Range of traded prices from listing on 15 Dec 2025 to 23 Oct 2026
₹1,336.60Low, 23 Dec 2025₹2,292.40High, 15 Sep 2026
- Next results date: the board meets on 30 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹12,545 Cr566th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 31 Jul 2026
- 63.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 11 May 2026
- 16.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.49%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 31 Jul 2026
- 26.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 31 Jul 2026
- 30.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 11 May 2026
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 34,97554.6% delivered
Who owns CORONA Remedies, filing by filing
Per cent of the company's shares. Every filing on record, from Dec 2025; the latest is the filing for Sep 2026.
Sep 2026 filing
- Promoters69.00%
- Foreign institutions4.21%
- Indian institutions16.45%
- Individuals and others10.34%
Shareholding pattern, per cent
- Promoters
- Foreign institutions
- Indian institutions
- Individuals and others
| Per cent | Dec 2025Filed 20 Jan | Mar 2026Filed 17 Apr | Jun 2026Filed 13 Jul | Sep 2026Filed 7 Oct |
|---|---|---|---|---|
| 69.00% | 69.00% | 69.00% | 69.00% | |
| Indian promoters | 69.00% | 69.00% | 69.00% | 69.00% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. | 31.00% | 31.00% | 31.00% | 31.00% |
| Shares in issue | 6,11,60,088 | 6,11,60,088 | 6,11,60,088 | 6,11,60,088 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. | 5,68,20,841 | 5,49,86,037 | 1,22,32,020 | 1,22,32,020 |
| Promoters' shares locked in | 4,21,97,968 | 4,21,97,968 | 1,22,32,020 | 1,22,32,020 |
A dash is a line the filing did not state. “Under 0.01%” is a holding of shares too small to show at two decimals.
CORONA Remedies promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is ANKURBHAI K MEHTA, 22.00%. The filing names 18 more members with no shares.Promoter buying and selling
| Holder | |||
|---|---|---|---|
| ANKURBHAI K MEHTAIndividuals and Hindu undivided families | 22.00% | 1,34,58,000 | 45.45% |
| NIRAV KIRTIKUMAR MEHTAIndividuals and Hindu undivided families | 22.00% | 1,34,58,000 | 45.45% |
| KIRTIKUMAR LAXMIDAS MEHTAIndividuals and Hindu undivided families | 20.00% | 1,22,29,307 | 0.00% |
| DIPABEN NIRAVKUMAR MEHTAIndividuals and Hindu undivided families | 2.00% | 12,22,047 | 0.00% |
| BRINDA ANKUR MEHTAIndividuals and Hindu undivided families | 2.00% | 12,22,047 | 0.00% |
| MINAXI KIRTIKUMAR MEHTAIndividuals and Hindu undivided families | 1.00% | 6,08,567 | 0.00% |
No promoter shares are reported as pledged. Locked in is the share of the holder's own shares that cannot be sold yet, as after a listing or an allotment.
Largest public holders of CORONA Remedies, filing by filing
Per cent, on the same shares as the split above.Mutual funds holding CORONA Remedies
| Holder | Dec 2025Filed 20 Jan | Mar 2026Filed 17 Apr | Jun 2026Filed 13 Jul | Sep 2026Filed 7 Oct |
|---|---|---|---|---|
| SEPIA INVESTMENTS LIMITEDForeign companies | 19.76% | 19.76% | 12.68% | 8.62% |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. Mutual funds are left out here: each fund's holding is on the Mutual funds tab, from its own portfolio. A dash is a filing that did not name the holder, which includes holding under one per cent.